Updates in Systemic Sclerosis Treatment and Applicability to Pediatric Scleroderma

Area of Science:

• Rheumatology
• Immunology
• Pediatrics

Background:

• Juvenile-onset systemic sclerosis (jSSc) is a rare, multisystem autoimmune disease characterized by inflammation and fibrosis.
• Current treatment protocols for jSSc are largely extrapolated from adult systemic sclerosis (SSc) management due to its rarity.
• Significant advancements in adult SSc research have yielded new therapies, particularly for SSc-associated interstitial lung disease.

Purpose of the Study:

• To review the current landscape of juvenile-onset systemic sclerosis (jSSc) treatment.
• To highlight recent therapeutic developments in adult systemic sclerosis (SSc) and their potential applicability to pediatric patients.
• To explore novel therapeutic strategies, such as autologous stem cell transplantation, for early intervention in jSSc.

Main Methods:

• Literature review of recent clinical trials and therapeutic advancements in adult and juvenile systemic sclerosis.
• Analysis of Food and Drug Administration (FDA)-approved therapies for SSc-associated interstitial lung disease.
• Exploration of emerging treatment modalities, including immunomodulatory and regenerative approaches.

Main Results:

• Two FDA-approved therapies now exist for SSc-associated interstitial lung disease in adults.
• Several ongoing clinical trials are investigating novel biological agents for SSc treatment.
• Autologous stem cell transplantation is emerging as a potential disease-halting strategy for early-stage jSSc.

Conclusions:

• Multifaceted treatment approaches, including pharmacologic therapy, supportive care, and lifestyle modifications, are essential for managing jSSc.
• Advances in adult SSc research provide a foundation for developing targeted therapies for pediatric patients.
• Early intervention with potentially curative therapies like stem cell transplantation holds promise for improving long-term outcomes in jSSc.